McDermott Will & Emery advised Galiena Capital, an independent specialist in investments in French SMEs, on the sale by Fleurus Edition of Ediser (Media-Participations), a specialist in educational engineering solutions for driving schools and professional training organizations.

This operation aimed to support Ediser’s development in the digitalization of driver training professionals, and to consolidate its leadership position in France and internationally.

The McDermott team advising Galiena Capital included :

• Diana Hund, Marie-Muriel Barthelet (partners) and Sarah Louifi (associate) on the corporate aspects of the transaction;
• Côme de Saint Vincent (counsel) and Oriane Beauvois (associate) on tax law;
• Pierre-Arnoux Mayoly (partner), Stanislas Chenu and Clarisse De Roux (associates) on financing aspects.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

McDermott Will & Emery has advised AREV, a specialist in European private equity investments, on its acquisition of a majority stake in Komposite, one of France’s leading data management specialists, alongside its management.

The aim of this operation is to support Komposite in its next phase of growth, notably by strengthening its position as technological leader and focusing its development plan on acquiring new customers, through organic and external growth.

Backed by Naxicap (formerly Alliance Entreprendre), BNP Paribas Développement, Rives Croissance, Caisse d’Epargne Ile de France and Financière Vecteur since 2020, AREV succeeds these funds as majority shareholder, while Eric Alimi, Harry Zarrouk and David Dariouch reinvest and retain a significant stake in the company.

The McDermott team that advised Arev included :

• Guillaume Kellner (partner), Stanislas Offroy and Auriane Tournay (associates) on the corporate aspects of the transaction;
• Pierre-Arnoux Mayoly (partner), Elisabeth Amzallag and Salomé Belhassen (associates) on financing;
• Antoine Vergnat (partner) and Paul-Henry de Laguiche (associate) on tax law;
• Naré Arshakyan (associate) in employment law.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

McDermott Will & Emery has advised Cilcare, a leading biotech company specializing in auditory sciences, on an exclusive Option Agreement with Shionogi, a pharmaceutical company, for innovative hearing disorder treatment.

This exclusive option agreement grants Shionogi the right to license global rights to CIL001 and/or CIL003, two promising drug candidates aimed at treating hearing disorders, with a particular focus on addressing the increasing prevalence of hidden hearing loss and tinnitus.

The McDermott team that advised Cilcare comprised:

• Emmanuelle Trombe, partner, Natacha Vasak and Oriana Castelli, associates, on corporate aspects
• Côme de Saint-Vincent, Counsel, on tax aspects
• Charles de Raignac, associate, on intellectual property aspects

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.

McDermott Will & Emery advised Owkin, the first TechBio unicorn to use cutting-edge causal AI to accelerate precision drug discovery, development and diagnostics, on an exclusive global license agreement with Idorsia (SIX: IDIA) to develop and commercialize OKN4395, a clinically-ready dual inhibitor of the EP2 and EP4 prostanoid receptors.

This license is part of an AI-driven oncology and immunology drug pipeline leveraging spatial multiomics data via MOSAIC, which enables Owkin to capture the tumor microenvironment in a way that few others can.

The McDermott team advising Owkin included Emmanuelle Trombe, Anne-France Moreau (partners), Lorraine Maisnier-Boché (counsel) and Caroline Noyrez. The team advised Owkin on the license with Idorsia, as well as on the contractual and data protection aspects of the MOSAIC project.

McDermott Will & Emery partners with leaders around the world to fuel missions, knock down barriers and shape markets. Our team works seamlessly across practices and industries to deliver highly effective solutions that propel success. More than 1,400 lawyers strong, we bring our personal passion and legal prowess to bear in every matter for our clients and the people they serve.